Novel Prognostic Biomarkers in Metastatic and Locally Advanced Colorectal Cancer: Micronuclei Frequency and Telomerase Activity in Peripheral Blood Lymphocytes

Frontiers in Oncology

Nikolaos Razos¹  John Tsiaoussis¹  Taxiarchis Konstantinos Nikolouzakis¹  Aristidis Tsatsakis²  John Souglakos³  Aikaterini Berdiaki⁴  Athanasios Alegakis⁵  Polychronis D. Stivaktakis⁵  Elena Vakonaki⁵ 

[1] Department of Anatomy, Medical School, University of Crete, Heraklion, Greece;Department of Forensic Sciences and Toxicology, Medical School, University of Crete, Heraklion, Greece;Department of Medical Oncology, University General Hospital of Heraklion, and Laboratory of Translational Oncology, Medical School, University of Crete, Heraklion, Greece;Laboratory of Histology-Embryology, Medical School, The University of Crete, Heraklion, Greece;Laboratory of Toxicology, Medical School, University of Crete, Heraklion, Greece;

关键词: metastatic colorectal cancer;    locally advanced rectal cancer;    micronuclei frequency;    telomerase activity;    biomarkers;    prognosis;   

DOI  :  10.3389/fonc.2021.683605

来源: DOAJ

【 摘 要 】

PurposeDue to the current practice on colorectal cancer (CRC) management, chemoresistance is most often recognized at the end of the treatment. Therefore, effective and easy-to-use prognostic biomarkers are needed.Experimental DesignWe evaluated the prognostic significance of two novel CRC biomarkers: a) micronuclei frequency (MNf) in 55 metastatic CRC (mCRC) and 21 locally advanced rectal cancer (laRC) patients using cytokinesis block micronucleus assay (CBMN assay) and b) telomerase activity (TA) in 23 mCRC and five laRC patients using TRAP-ELISA. Both biomarkers were evaluated in peripheral blood lymphocytes (PBLs) before, at the middle, and at the end of the therapy (approximately 0, 3, and 6 months) for mCRC patients before, at the end of the therapy, and after surgery for laRC patients.ResultsOverall, MNf demonstrated significant prognostic value since a decrease of MNf less than 29% between middle and initial MNf measurements can discriminate between progressive and stable/responsive disease with sensitivity of 36% and specificity of 87.0% while being able to identify responsive disease with sensitivity of 72.7% and specificity of 59.3%. On the other hand, TA presented a significant trend of increase (p = 0.07) in patients with progressive disease at the middle measurement.ConclusionsThe findings of this study suggest that the MN frequency may serve as a promising prognostic biomarker for the monitoring of the treatment response of patients with CRC, while TA should be evaluated in a larger group of patients to further validate its significance.

【 授权许可】

Unknown